SCHEINBERG DAVID A 4
4 · SELLAS Life Sciences Group, Inc. · Filed Dec 29, 2017
Insider Transaction Report
Form 4
SCHEINBERG DAVID A
Director
Transactions
- Award
Common Stock
2017-12-29+9,107→ 9,107 total
Footnotes (2)
- [F1]In connection with the merger of SELLAS Life Sciences Group, Ltd ("SELLAS") and a wholly owned indirect subsidiary of the Issuer (then known as Galena Biopharma, Inc.) (the "Merger"), outstanding restricted stock units ("RSUs") to be settled in SELLAS common shares were assumed by the Issuer and will be settled in shares of the Issuer's common stock based on the following exchange ratio: 43.9972 shares of the Issuer's common stock for each common share of SELLAS.
- [F2]Represents shares issuable upon vesting of RSUs. 100% of the shares subject to the RSUs will vest on February 27, 2018.